Jefferies Maintains a 'Buy' on NxStage Medical (NXTM); Adjusting Outlook

Article Stock Quotes (1) Comments (0)

Jefferies maintains a 'Buy' on NxStage Medical (NASDAQ: NXTM) price target of $21.00.

Analyst, Raj Denhoy, said, "Following last week’s 2Q earnings, we’ve revisited our NXTM model and made some minor tweaks, most notably a tempering of our sequential US home hemodialysis revenue growth assumptions for the back half offset somewhat by slightly higher sales projections for international HHD. Overall, there are no material changes to our forecasts, nor our long-term investment thesis."

Sees current quarter EPS at (0.07), FY at (0.31) and next year at (0.09)

For an analyst ratings summary and ratings history on NxStage Medical click here. For more ratings news on NxStage Medical click here.

Shares of NxStage Medical closed at $13.10 yesterday, with a 52 week range of $12.96-$24.06.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
• Toll Bros. (TOL) Estimates/PT Raised at Compass Point
• Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Jefferies & Co, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?